{
    "nct_id": "NCT00471211",
    "title": "A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Three-Group Study to Assess the Safety, Tolerability and Efficacy of Two Dose Levels of PBT2 to Slow Progression of Disease in Patients With Early Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2008-01-13",
    "description_brief": "The purpose of the study is to determine the safety, tolerability and efficacy of 2 doses of PBT2 administered for 12 weeks compared to placebo in patients with early Alzheimer's disease treated with an acetylcholinesterase inhibitor.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "PBT2 (metal\u2011protein attenuating compound \u2014 small molecule Cu/Zn ionophore targeting A\u03b2 oligomerisation)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests PBT2, which is described in the literature as a metal\u2011protein attenuating compound (MPAC) that modulates copper/zinc interactions with amyloid\u2011\u03b2 to reduce A\u03b2 oligomerisation \u2014 i.e., it targets Alzheimer\u2019s pathology rather than being a biologic or purely symptomatic cognitive enhancer. \ue200cite\ue202turn1search4\ue202turn0search0\ue201",
        "Act: The cited trial is a 12\u2011week, randomized, double\u2011blind, placebo\u2011controlled Phase 2 study (NCT00471211) of two oral dose levels of PBT2 versus placebo in patients with early Alzheimer\u2019s disease; the study reports biomarker (CSF A\u03b242) changes and some cognitive (executive function) findings. This confirms the intervention and intent to modify disease\u2011related pathology. \ue200cite\ue202turn0search6\ue202turn1search4\ue201",
        "Evidence: The Phase IIa report notes a dose\u2011dependent reduction in CSF A\u03b242 and improvements on two executive function tests at 250 mg, consistent with a central effect on A\u03b2 metabolism rather than a non\u2011specific symptomatic agent. \ue200cite\ue202turn1search0\ue202turn1search4\ue201",
        "Classification decision (Reflect): PBT2 is a small molecule MPAC (not a biologic such as an antibody or vaccine), and its mechanism and trial endpoints aim at modifying Alzheimer\u2019s pathology (amyloid biology). Therefore the correct category is 'disease-targeted small molecule'. Note: although some cognitive test improvements were observed, those are downstream outcomes of the disease-targeting mechanism rather than primary symptomatic (non\u2011pathology) cognitive enhancement. \ue200cite\ue202turn1search4\ue202turn0search3\ue201",
        "Web search results used (key sources): Lancet Neurology Phase IIa trial reporting PBT2 mechanism and trial results (Lannfelt et al., 2008). \ue200cite\ue202turn1search4\ue201; PubMed / J Neurochem mechanistic study on PBT2 metal\u2011chaperone activity. \ue200cite\ue202turn0search0\ue201; ClinicalTrials registry entry for NCT00471211 / trial listing. \ue200cite\ue202turn0search6\ue202turn1search5\ue201; review/chemistry context describing PBT2 as a Cu/Zn ionophore / MPAC. \ue200cite\ue202turn0search3\ue202turn0search7\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational drug PBT2 is a metal\u2011protein attenuating compound (MPAC) / Cu/Zn ionophore described in the literature as modulating copper and zinc interactions with amyloid\u2011\u03b2 to reduce A\u03b2 oligomerisation and affect A\u03b2 metabolism. This mechanism directly targets amyloid biology rather than only providing symptomatic benefit. \ue200cite\ue202turn0search6\ue202turn0search1\ue201",
        "Act: Extracted details from the trial description and publications: PBT2 is a small\u2011molecule MPAC (Cu/Zn ionophore) given orally; the Phase IIa trial (12\u2011week, randomized, double\u2011blind, placebo\u2011controlled; NCT00471211 / Lannfelt et al., Lancet Neurol 2008) tested 50 mg and 250 mg versus placebo in early AD and reported a dose\u2011dependent reduction in CSF A\u03b242 and improvement on two executive\u2011function tests at 250 mg. These outcomes confirm the intervention is intended to modify amyloid pathology. \ue200cite\ue202turn0search6\ue202turn0search5\ue202turn0search0\ue201",
        "Reflect: The primary biological focus is modification of amyloid\u2011\u03b2 oligomerisation/metabolism via metal ion modulation. Although PBT2 also perturbs metal homeostasis and has downstream effects (e.g., signaling changes reported in mechanistic studies), the trial and preclinical rationale explicitly target A\u03b2 biology. Therefore the most specific CADRO category is A) Amyloid beta, not multi\u2011target or Other. \ue200cite\ue202turn0search1\ue202turn0search7\ue201",
        "Web search results used (key sources cited above):",
        "- Lannfelt L et al., Lancet Neurol 2008 \u2014 Phase IIa trial reporting PBT2 as an MPAC, trial design (12 weeks), CSF A\u03b242 reduction and cognitive findings (NCT00471211). \ue200cite\ue202turn0search6\ue202turn0search5\ue201",
        "- PubMed summary / analyses reporting cognitive and biomarker outcomes from the PBT2 Phase IIa study. \ue200cite\ue202turn0search0\ue201",
        "- Mechanistic studies showing PBT2 metal\u2011chaperone activity, promotion of A\u03b2 degradation and downstream signaling effects. \ue200cite\ue202turn0search1\ue202turn0search7\ue201"
    ]
}